Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9281543 | 0.98 | GAA (0.44) | GAAMAPTL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL245979 | 0.81 | ALDH1A1 (0.49) | GAAMAPTL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL16166710 | 0.79 | ALDH1A1 (0.47) | GAAMAPTL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL4948816 | 0.78 | ALDH1A1 (0.42) | GAAMAPTL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL34465669 | 0.77 | MAPT (0.38) | GAAMAPTL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL11124858 | 0.77 | ALDH1A1 (0.41) | GAAMAPTL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL10579425 | 0.77 | GAA (0.47) | GAAMAPTL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL3964474 | 0.76 | ALDH1A1 (0.45) | GAAMAPTL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL27636931 | 0.76 | DGAT1 (0.46) | GAAMAPTL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL7782632 | 0.76 | KDM4E (0.51) | GAAMAPTL3MBTL1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8741934-B2 | Inhibitors of ion channels | PFIZER LIMITED (GB) | 2014-06-03 | — | — | US | disclosed |
| US-20130072471-A1 | Inhibitors of Ion Channels | MARRON BRIAN EDWARD (US) | 2013-03-21 | — | — | US | disclosed |
| EP-2358686-B1 | ARYL METHYL BENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2012-09-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072471-A1 | Inhibitors of Ion Channels | TRPV1, TRPV5, TRPA1 | GAA 3679/4885MAPT 2938/4885L3MBTL1 4718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.